Stem Cell Research, Toward the Ultimate Cure

Won Shik Choi | Science 100 | wonshik@ualberta.ca | University of Alberta, Edmonton, AB



1. Introduction

Death is human destiny, which all human beings must go through. There are many reasons for death, however, the most common factors are the following: aging, accidents, and disease.

A human is a package of cells that are programmed to die after around 50 cycles of replication. If the aged or damaged cells cannot be replaced due to some infections, the person dies.

In order to treat some of the diseases, doctors commonly use surgery, chemotherapy, etc.

Using a mechanism that humans naturally have, using stem cells, researchers proposed a transplant therapy to successively replace the damaged cells.

3. Embryonic Stem Cells(ESC)

Embryonic stem cell research enhanced medicine in many different ways. It allowed better transplant therapy. ESCs provide donor sources for diseases such as juvenile diabetes, Parkinson's disease, and heart failure.

One of the strong advantages that ESCs have is that they can self-replicate easily. It can be replicated on the cell culture; thus, researchers can derive particular cells or organs in order to test their drugs.

Despite their strong advantages, there are limitations of this therapy, such as limited resources of ESCs and the ethical issue following with it. Most of the embryos used in the research are mostly donated, but due to the ethical issues, it is really hard to get a sufficient enough number for the research.



5. Ethical Controversy


The fresh human embryos involved in stem cell research are produced by in vitro fertilization with consent of their parent.

The usage of human embryos faces ethical controversy that inhibits the embryonic stem cell research. That's because the criteria of defining life is not clear. Because some people consider the embryo as a living thing, killing embryos during the process of stem cell therapy involves ethical controversy.





2. Somatic vs. Embryonic Stem Cells



Embryonic stem cells can be derived from a blastocyst of a mammalian embryo.

Human bodies have their own mechanism to replace damaged cells by using somatic stem cells (adult stem cells). They both exhibit characteristic of pluripotency and self-renewability.

Somatic stem cells can be differentiated into only certain types of cells (restricted to organ source), whereas, embryonic can be differentiated into all 3 types of germ layers.


Fertilized Blastocyst ovum cell mass Neural cells ES cells **Body** Reprogramming Beta cells iPS cells Blood SC Blood cells Adipose tissue SC Bone marrow SC Hepatocytes Multipotent stem cells Cardiac cells

4. Induced Pluripotent Stem Cells (iPS cells)

The successful reprogramming of human somatic cells into a pluripotent state makes induced pluripotent stem cells. The reprogramming is the reverse steps of cell differentiation. The somatic cells of the patient can be reprogrammed, with some modification, to become iPS cells. Because it's using the patient's somatic cell, it has a higher chance of generation of successful patient- and disease- specific stem cells.

There are four commonly known currently available techniques to generate iPS cells. It can be generated by nuclear transfer from somatic cells to Oocyte, nuclear fusion between somatic cells and embryonic stem cells, culturing germline stem cells and parthenogenetic embryos bone marrow cells, and putting some defined factors into somatic cells.

There are ethical issues involving some of the induced pluripotent stem cells.




6. iPS cells generated by defined factors

Researchers have found the pluripotency of the embryonic stem cells are induced by the four factors, Oct-3/4, Sox2, c-Myc, and Klf4. Turns out, simply introducing the factors into the patient's somatic cells can induce the pluripotency of the somatic cells.

Researchers could eliminate the requirement of human embryos by using the defined factors, which indicates they are free from the ethical controversy.

Tumorigenicity

However, using this method, less than 1% of the cells that put genes transcribing four defined factors can be reprogrammed into iPS cells. This is because, out of 4 defined factors, c-Myc and Klf 4 are cancer-associated transcription factors.



Conclusion

Future of stem cell therapy

Stem cell therapy is a relatively recently developed technique. A lot of researchers around the world are working on some of the limitations and trying to come up with a better method and technique for stem cell therapy. There is no such better technique over others. However researchers believe that stem cell therapy, overall, is an ultimate cure and can possibly treat the full range of untreatable diseases in our future.

References

ttps://www.asdreports.com/media/PR 1943.ipg

Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, et al. 2006. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125(2):315-26.

Evans MJ and Kaufman MH. 1981. Establishment in culture of pluripotential cells from mouse embryos. Nature 292(5819):154-6.

Hwang WS, Roh SI, Lee BC, Kang SK, Kwon DK, Kim S, Kim SJ, Park SW, Kwon HS, Lee CK, et al. 2005. Developmental biology: Patient-specific embryonic stem cells derived from human SCNT biastocysts. Science 308(5729):1777-83.

Jang HJ, Kim JS, Choi HW, Jeon I, Choi S, Kim MJ, Song J, Do JT. 2014. Neural stem cells derived from epiblast stem cells display distinctive properties. Stem Cell Research 12(2):506-16.

Kim J-, Auerbach JM, Rodríguez-Gómez JA, Velasco I, Gavin D, Lumelsky N, Lee S-, Nguyen J, Sánchez-Pernaute R, Bankiewicz K, et al. 2002. Dopamine neurons derived from embryonic stem cells function in an animal model of parkinson's disease. Nature 418(6893):50-6.

Kimura H, Tada M, Nakatsuji N, Tada T. 2004. Histone code modifications on pluripotential nuclei of reprogrammed somatic cells. Mol Cell Biol 24(13):5710-20.

Lee J-, Hart SRL, Skalnik DG. 2004. Histone deacetylase activity is required for embryonic stem cell differentiation. Genesis 38(1):32-8.

Okita K, Ichisaka T, Yamanaka S. 2007. Generation of germline-competent induced pluripotent stem cells. Nature 448(7151):313-7.

Takahashi K, and Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 131(5):861-72.

Tesar PJ, Chenoweth JG, Brook FA, Davies TJ, Evans EP, Mack DL, Gardner RL, McKay RDG. 2007. New cell lines from mouse epiblast share defining features with human embryonic stem cells. Nature 448(7150):196-9.

Thomson JA. 1998. Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145-7.

Yamanaka S. 2007. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell St

hou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, et al. 2009. Generation of induced pluripotent stem cells using!

http://25.media.tumblr.com/tumblr_m7xd9r62oh1qzcf71o1_500.ipg http://videos.videopress.com/PJJgsmYh/cell_256k.original.ipg http://www.industrytap.com/first-successful-cloned-stem-cells-created-from-human-skin-cells/6580